Table 3.
Data from 46 adjuvant radiotherapies from 43 patients
| Variables | Value |
|---|---|
| Age at adjuvant radiotherapy (years) | |
| Mean/SD/median/range | 64.8/5.81/65.3/75 - 54 |
| Time from salvage lymph node dissection to adjuvant RT (months) | |
| Mean/SD/median/range | 2.75/1.72/2.20/8.4 - 0.8 |
| Region for adjuvant RT n (%) | |
| Pelvic right only | 2/46 (4.3%) |
| Pelvic left only | 5/46 (10.9%) |
| Pelvic only (left/right/bilateral) | 26/46 (57%) |
| Retroperitoneal only | 5/46 (11%) |
| Pelvic and retroperitoneal | 14/46 (30%) |
| Retroclavicular and retroperitoneal | 1/46 (2%) |
| Cases with dose escalation on involved region n (%) | 11/46 (24.0%) |
| Method of adjuvant radiotherapy | |
| 3D-conformal radiotherapy n (%) | 29/46 (63%) |
| IMRT n (%) | 17/46 (37.0%) |
| Concurrent radiation of prostatic fossa n (%) | 12/46 (26.1%) |
| Total dose for radiation of prostatic fossa (Gy) | |
| Mean/SD/median/range | 69.18/2.38/70.20/45.0 – 72.2 |
| Duration of adjuvant radiotherapy (months) | |
| Mean/SD/median/range | 1.39/0.35/1.37/2.4 – 1.0 |
| Dose per fraction (Gy) | 1.8, 5x1.8/week |
| Total dose for pelvic or retroperitoneal RT (Gy) | |
| Mean/SD/median/range | 49.55/4.16/50.40/45.0 – 59.4 |
| Number of cases with concurrent AHT at radiotherapy n (%) | 2/46 (4.3%) |
| Patients with concurrent AHT at latest follow up | 27/43 (62.8%) |
| Comorbidities at latest follow1 up n (%) | |
| Cardiovascular disease n (%) | 10/38 (26.4%) |
| Diabetes mellitus n (%) | 3/38 (7.9%) |
| Concurrent malignant disease n (%) | 3/38 (7.9%) |
| Chronic disease/chronic pain n (%) | 6/38 (15.9%) |
RT = Radiotherapy.
AHT = Antihormonal therapy.
IMRT = Intensity-modulated radiation therapy.
1Mean 3.2 (SD: 2.8) years after end of radiotherapy.